From Half-Life to Full-Life.
Full-Life Technologies Limited (“Full-Life”) is a fully integrated RadioTherapeutics company with operations in Europe, the United States, and China.
-
Global management team with decades of experience spanning the discovery, development, production, and logistics of radiopharmaceuticals.
About our team -
We attach the radionuclide to the targeting vector (single domain antibody or peptide) which delivers the payload directly to the tumor.
About our pipeline -
Our radiotechnology platform takes a wholistic approach covering production and logistics of radiopharmaceutical drug products.
About our technology
Full-Life Technologies Announces Appointment of Steffen Heeger, MD, PhD, as Chief Medical Officer and Fa Liu, PhD, as Chief Scientific Officer
-
Nov 29, 2022
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
-
Aug 10, 2022
Full-Life Technologies Deepens Radioisotope Technology Expertise with Key Leadership Appointments and the Establishment of a Radioisotope Technology Advisory Board
-
Follow Us
-
-
General Inquiries
-
Contact Us
